Ernst & Young: Pricing Pressure Trumps Drug Safety As Industry’s Top Worry
This article was originally published in The Pink Sheet Daily
Executive Summary
Reimbursement now “end goal of a firm’s clinical development efforts,” risk report says.
You may also be interested in...
Ernst & Young: “Optionality” Here To Stay, As Biotech Business Model Reinvents Itself
Chaos in the capital markets may force shortened R&D timelines that result in structured acquisitions, novel deal structures, and a boom in personalized medicine.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.